Last $14.33 USD
Change Today +0.01 / 0.07%
Volume 38.1K
ADMS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

adamas pharmaceuticals inc (ADMS) Snapshot

Open
$13.95
Previous Close
$14.32
Day High
$14.60
Day Low
$13.95
52 Week High
05/1/14 - $21.63
52 Week Low
04/11/14 - $12.02
Market Cap
240.1M
Average Volume 10 Days
85.5K
EPS TTM
--
Shares Outstanding
16.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADAMAS PHARMACEUTICALS INC (ADMS)

Related News

No related news articles were found.

adamas pharmaceuticals inc (ADMS) Related Businessweek News

No Related Businessweek News Found

adamas pharmaceuticals inc (ADMS) Details

Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company’s lead product candidate, ADS-5102, is being developed for a complication of Parkinson’s disease, known as levodopa-induced dyskinesia, and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. Its portfolio also includes an NDA-submitted fixed-dose combination product candidate, MDX-8704, which is being co-developed with Forest Laboratories, Inc.; and an approved controlled-release product, Namenda XR. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

29 Employees
Last Reported Date: 08/7/14
Founded in 2000

adamas pharmaceuticals inc (ADMS) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $728.0K
Senior Vice President of Product Development
Total Annual Compensation: $561.5K
Compensation as of Fiscal Year 2013.

adamas pharmaceuticals inc (ADMS) Key Developments

Adamas Pharmaceuticals, Inc. Announces Management Changes

Jeffrey (Jeff) Knapp has been named Chief Operating Officer. In this newly created role, Mr. Knapp will continue to lead the build out of the sales and marketing organization, and will also oversee commercial operations, manufacturing, corporate development, medical affairs, alliance management and contracts. Mr. Knapp joined Adamas as Chief Commercial Officer at the beginning of 2014. He brings more than 25 years of commercial and operations experience in the pharmaceutical/biotechnology industry. Prior to Adamas, Mr. Knapp spent seven years as the Chief Commercial Officer for Affymax where he was responsible for building its U.S. commercial organization and leading the launch of the company's first product for the treatment of anemia. William (Bill) J. Dawson has been named Chief Financial Officer, replacing Anthony (Tony) Rimac. Mr. Dawson will be responsible for financial strategy, financial planning and analysis, accounting, compliance, and SEC reporting and will play a key role in investor relations, corporate strategy and planning. Mr. Dawson was most recently a consultant to a number of companies, including Adamas. Previously he served as Chief Financial Officer at Catalyst Biosciences, Inc., from 2010 to 2012. Both Mr. Knapp and Mr. Dawson will report to Gregory Went, PhD., Chairman and Chief Executive Officer.

Adamas Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Adamas Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $25.154 million against $0.241 million a year ago. Income from operations was $16.719 million against loss from operations of $2.694 million a year ago. Income before income taxes was $16.607 million against loss before income taxes of $3.261 million a year ago. Net income was $16.429 million against net loss of $3.353 million a year ago. Diluted net income attributable to common stockholders was $16.429 million or $0.88 per share against $3.353 million or $0.35 per share a year ago. The difference between the two periods was primarily the result of the recognition of revenue associated with the collaboration with Forest Laboratories, Inc. For the six months, the company reported revenue of $25.330 million against $30.824 million a year ago. Income from operations was $11.028 million against $24.691 million a year ago. Income before income taxes was $10.228 million against $23.703 million a year ago. Net income was $10.049 million against $23.416 million a year ago. Diluted net income attributable to common stockholders was $8.162 million or $0.53 per share against $15.928 million or $1.43 per share a year ago.

Adamas Pharmaceuticals, Inc. Presents at 5th Annual Credit Suisse Small & Mid Cap Conference, Sep-16-2014 09:30 AM

Adamas Pharmaceuticals, Inc. Presents at 5th Annual Credit Suisse Small & Mid Cap Conference, Sep-16-2014 09:30 AM. Venue: The Waldorf Astoria, 301 Park Avenue (between 49th & 50th Streets), New York, New York, United States. Speakers: Danny Herron, CFO, Garry Rogerson, CEO, Gregory T. Went, Chairman and Chief Executive Officer, Julie Wood, VP, Corporate Communications.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMS:US $14.33 USD +0.01

ADMS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADMS.
View Industry Companies
 

Industry Analysis

ADMS

Industry Average

Valuation ADMS Industry Range
Price/Earnings 5.3x
Price/Sales 3.4x
Price/Book 1.7x
Price/Cash Flow 6.4x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADAMAS PHARMACEUTICALS INC, please visit www.adamaspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.